934417-60-4

Upstream product

• 27129-86-8 1-bromomethyl-3,5-dimethylbenzene 
• 1635-61-6 5-chloro-2-nitroaniline 

Downstream Products

• 934417-62-6 2-amino-5-chloro-1-(3,5-dimethylbenzyl)aniline 
• 1562665-64-8 2-{[6-chloro-1-(3,5-dimethylbenzyl)-1H-benzimidazol-2-yl]sulfanyl}-N-[2-chloro-4-(methylsulfonyl)phenyl]acetamide 
• 1562665-51-3 methyl 3-chloro-4-(2-(6-chloro-1-(3,5-dimethylbenzyl)-1H-benzo[d]imidazol-2-ylthio)acetamido)benzoate 
• 1562665-37-5 C₂₅H₂₃Cl₂N₃OS 
• 1562665-12-6 2-{[6-chloro-1-(3,5-dimethylbenzyl)-1H-benzimidazol-2-yl]sulfanyl}-N-2-nitrophenylacetamide 
• 1562664-93-0 2-{[6-chloro-1-(3,5-dimethylbenzyl)-1H-benzimidazol-2-yl]sulfanyl}-N-2-bromophenylacetamide 
• 1562664-80-5 2-{[6-chloro-1-(3,5-dimethylbenzyl)-1H-benzimidazol-2-yl]sulfanyl}-N-2-chlorophenylacetamide 
• 1061732-18-0 6-chloro-1-(3,5-dimethylbenzyl)-1,3-dihydro-2H-benzimidazole-2-thione 
• 1562665-93-3 2-{[6-chloro-1-(3,5-dimethylbenzyl)-1H-benzimidazol-2-yl]sulfanyl}-N-(2-chloro-4-sulfamoylphenyl)acetamide 
• 934417-58-0 C₁₆H₁₅ClN₂O 

Relevant academic research and scientific papers

Discovery of benzimidazole-based Leishmania mexicana cysteine protease CPB2.8ΔCTE inhibitors as potential therapeutics for leishmaniasis

Chemotherapy is currently the only effective approach to treat all forms of leishmaniasis. However, its effectiveness is severely limited due to high toxicity, long treatment length, drug resistance, or inadequate mode of administration. As a consequence,

Design and synthesis of N1-aryl-benzimidazoles 2-substituted as novel HIV-1 non-nucleoside reverse transcriptase inhibitors

A series of novel N1-aryl-2-arylthioacetamido-benzimidazoles were synthesized and evaluated as inhibitors of human immunodeficiency virus type-1 (HIV-1). Some of them proved to be effective in inhibiting HIV-1 replication at submicromolar and nanomolar concentration acting as HIV-1 non-nucleoside RT inhibitors (NNRTIs), with low cytotoxicity. The preliminary structure-activity relationship (SAR) of these new derivatives was discussed and rationalized by docking studies.

Novel N1-substituted 1,3-dihydro-2H-benzimidazol-2-ones as potent non-nucleoside reverse transcriptase inhibitors

Several N1-substituted 1,3-dihydro-2H-benzimidazol-2-ones were synthesized and evaluated as anti-HIV agents. Some of them proved to be highly effective in inhibiting HIV-1 replication at nanomolar concentration as potent non-nucleoside HIV-1 RT

Discovery of novel benzimidazolones as potent non-nucleoside reverse transcriptase inhibitors active against wild-type and mutant HIV-1 strains

Molecular modeling studies led to the rational discovery of N1-arylsulfonyl-1,3-dihydro-2H-benzimidazol-2-one as a novel template for the design of new non-nucleoside reverse transcriptase inhibitors (NNRTIs) that are active against wild-type a